TG Therapeutics Inc (STU:NKB2)
€ 14.742 -0.034 (-0.23%) Market Cap: 2.35 Bil Enterprise Value: 2.26 Bil PE Ratio: 75.14 PB Ratio: 15.96 GF Score: 72/100

TG Therapeutics Inc at B Riley Fall Growth Biotech Best Ideas Series (Virtual) Transcript

Nov 11, 2021 / 05:00PM GMT
Release Date Price: €28.93 (+1.40%)
Mayank Mamtani
B. Riley Securities, Inc., Research Division - MD & Group Head of Healthcare

Good afternoon, and good morning to folks on the West side of the country. Apologies for the slight delay here in starting up. So we are welcoming you to our fall 2021 Best Idea Series, the fifth chapter. This is Mayank Mamtani, senior biotech analyst representing the broader health care research efforts in bringing to you all our top ideas within this mid-cap therapeutics space that we think remain attractive despite an otherwise duct tape in biotech, although there is some life in the recent days and weeks.

So with that presenting, our next idea TG Therapeutics, ticket TGTX, where I'm pleased to have with me Mike Weiss, Chairman, President and CEO. Thanks so much, Mike, for joining us. But before we get started, I need to make the following quick disclosures. In the normal course of business, B. Riley Securities seek to perform investment banking and other services for companies under coverage and to receive compensation in connection for such said services. In addition, B. Riley makes a market for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot